<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04282148</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10321</org_study_id>
    <nct_id>NCT04282148</nct_id>
  </id_info>
  <brief_title>Abbott Next Generation Drug Eluting Stent 48mm Study</brief_title>
  <acronym>SPIRIT 48</acronym>
  <official_title>A Clinical Investigation to Assess the Abbott Next Generation Drug Eluting Stent 48mm Everolimus Eluting Coronary Stent System (EECSS) in Treatment of de Novo Native Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this SPIRIT 48 study is to evaluate the safety and effectiveness of the ABT NG&#xD;
      DES 48 in improving coronary artery luminal diameter in subjects with coronary artery disease&#xD;
      (CAD) due to de novo native coronary artery long lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SPIRIT 48 mm study is a prospective, single arm, open-label, multi-center global (US and&#xD;
      outside of US) clinical investigation to evaluate the safety and effectiveness of the ABT&#xD;
      Next Generation Drug Eluting Stent 48 mm everolimus-eluting coronary stent system (EECSS)&#xD;
      (called &quot;ABT NG DES 48&quot;) in up to 107 subjects at up to 33 sites globally. The clinical&#xD;
      outcomes from the SPIRIT 48 study will be compared to a performance goal (PG) established&#xD;
      using historical control data from the SPIRIT Prime Long Lesion Registry. This clinical&#xD;
      investigation will be conducted under an investigational device exemption (IDE) and is&#xD;
      intended to support market approval of the ABT NG DES 48 in the United States.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2020</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, multi-center, global (US and OUS)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Target Lesion Failure (TLF)</measure>
    <time_frame>1 year</time_frame>
    <description>Target Lesion Failure (TLF) is defined as the composite rate of cardiac death (CD), target vessel myocardial infarction [TV-MI] (per SCAI MI definition), and clinically indicated target lesion revascularization [CI-TLR])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Target Lesion Failure (TLF)</measure>
    <time_frame>In-hospital 6 to 12 hours post procedure</time_frame>
    <description>Target Lesion Failure (TLF) is defined as the composite rate of cardiac death (CD), target vessel myocardial infarction [TV-MI] (per SCAI MI definition), and clinically indicated target lesion revascularization [CI-TLR])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Target Lesion Failure (TLF)</measure>
    <time_frame>30 days</time_frame>
    <description>Target Lesion Failure (TLF) is defined as the composite rate of cardiac death (CD), target vessel myocardial infarction [TV-MI] (per SCAI MI definition), and clinically indicated target lesion revascularization [CI-TLR])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Target Lesion Failure (TLF)</measure>
    <time_frame>180 days</time_frame>
    <description>Target Lesion Failure (TLF) is defined as the composite rate of cardiac death (CD), target vessel myocardial infarction [TV-MI] (per SCAI MI definition), and clinically indicated target lesion revascularization [CI-TLR])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Target Lesion Failure (TLF)</measure>
    <time_frame>2 years</time_frame>
    <description>Target Lesion Failure (TLF) is defined as the composite rate of cardiac death (CD), target vessel myocardial infarction [TV-MI] (per SCAI MI definition), and clinically indicated target lesion revascularization [CI-TLR])</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">107</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>ABT NG DES 48 EECSS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABT NG DES 48 EECSS device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ABT NG DES 48 EECSS</intervention_name>
    <description>Each participant will receive ABT NG DES 48 EECSS with appropriate diameter</description>
    <arm_group_label>ABT NG DES 48 EECSS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be at least 18 years of age.&#xD;
&#xD;
          2. Subject or a legally authorized representative must provide written informed consent&#xD;
             prior to any study related procedure, per site requirements.&#xD;
&#xD;
          3. Subject must have evidence of myocardial ischemia (e.g., unstable angina, post-infarct&#xD;
             angina, stable angina or silent ischemia) suitable for non-emergent PCI. Subject with&#xD;
             stable angina or silent ischemia must have objective sign of ischemia as suggested by&#xD;
             one of the following,&#xD;
&#xD;
               -  Abnormal stress or imaging stress test&#xD;
&#xD;
               -  Abnormal computed tomography-fractional flow reserve (CT-FFR)&#xD;
&#xD;
               -  Stenosis by visual estimation ≥ 70%&#xD;
&#xD;
               -  Abnormal pressure-derived indexes (FFR, instantaneous wave-free ratio [iFR], or&#xD;
                  relative flow reserve [RFR])&#xD;
&#xD;
          4. Subject must be an acceptable candidate for coronary artery bypass graft (CABG)&#xD;
             surgery.&#xD;
&#xD;
          5. Subject must agree not to participate in any other clinical study for a period of one&#xD;
             year following the index procedure.&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
          1. Only one de novo target lesion in native coronary artery is allowed to be treated with&#xD;
             the investigational stent.&#xD;
&#xD;
             • One additional non-target lesion can be treated if it is located in a different&#xD;
             epicardial coronary vessel and NOT in left main coronary artery. The non-target lesion&#xD;
             must be treated first and must be deemed an angiographic success.&#xD;
&#xD;
          2. The target lesion must be located in a native coronary artery with:&#xD;
&#xD;
               -  Visually estimated reference vessel diameter (RVD) of ≥ 2.5 mm and ≤ 4.25 mm.&#xD;
&#xD;
               -  Visually estimated lesion length of &gt; 32 mm and ≤ 44 mm, and able to be covered&#xD;
                  by a single ABT NG DES 48.&#xD;
&#xD;
                  a. Multiple focal de novo lesions in an epicardial coronary vessel are allowed if&#xD;
                  the lesions can be covered by one stent. Multiple focal de novo lesions will be&#xD;
                  counted as a single lesion.&#xD;
&#xD;
               -  Visually estimated diameter stenosis of &gt; 50% and &lt; 100% with a Thrombolysis in&#xD;
                  Myocardial Infarction (TIMI) flow of ≥ 1&#xD;
&#xD;
                    1. Stable angina or silent ischemia subjects must have stenosis ≥ 70%, or&#xD;
                       abnormal pressure-derived physiological indices (FFR, iFR, or RFR), unless&#xD;
                       abnormal stress or imaging stress test is evidenced.&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          1. Subject has known hypersensitivity or contraindication to device material and its&#xD;
             degradants (everolimus, cobalt, chromium, nickel, tungsten, acrylic and&#xD;
             fluoropolymers, etc.), or has known contrast sensitivity.&#xD;
&#xD;
          2. Subject has known hypersensitivity or contraindication to aspirin,&#xD;
             heparin/bivalirudin, P2Y12 inhibitors (clopidogrel /prasugrel /ticagrelor), and&#xD;
             therefore cannot be adequately pre-medicated.&#xD;
&#xD;
          3. Subject has a planned surgery or procedure necessitating discontinuation of aspirin or&#xD;
             P2Y12 inhibitor within 12 months following index procedure.&#xD;
&#xD;
          4. Subject is receiving or will require chronic anticoagulation therapy (e.g., coumadin,&#xD;
             dabigatran, apixaban, rivaroxaban or any other agent for any reason).&#xD;
&#xD;
          5. Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year&#xD;
             following index procedure. Female subjects of child-bearing potential must have a&#xD;
             negative pregnancy test done within 7 days prior to the index procedure per site&#xD;
             standard test.&#xD;
&#xD;
          6. Subject had an acute myocardial infarction (AMI) within 48 hours of the index&#xD;
             procedure with either of the situations below:&#xD;
&#xD;
               -  The subject is currently experiencing clinical symptoms consistent with new onset&#xD;
                  AMI, such as nitrate-unresponsive prolonged chest pain with ischemic&#xD;
                  electrocardiogram (ECG) changes&#xD;
&#xD;
               -  Elevated cardiac biomarker values have not returned to within normal limits at&#xD;
                  the time of index procedure.&#xD;
&#xD;
          7. Subject has a left ventricular ejection fraction (LVEF) &lt; 30% within 3 months prior to&#xD;
             the index procedure, that was documented by any method.&#xD;
&#xD;
          8. Subject is expected to require percutaneous mechanical cardiac support at the index&#xD;
             procedure.&#xD;
&#xD;
          9. Prior PCI within the target vessel during the last 12 months prior to consent.&#xD;
&#xD;
         10. Prior PCI within the non-target vessel or any peripheral intervention during the last&#xD;
             30 days prior to consent.&#xD;
&#xD;
         11. At the index procedure, subject is identified to require planned stenting procedure&#xD;
             (including staged procedures) or CABG after the index procedure.&#xD;
&#xD;
         12. Subject has received a solid organ transplant which is functioning or is active on a&#xD;
             waiting list for any solid organ transplants with expected transplantation within 24&#xD;
             months.&#xD;
&#xD;
         13. Subject has a malignancy that is not in remission.&#xD;
&#xD;
         14. Subject is receiving immunosuppressant therapy or has known life-threatening&#xD;
             immunosuppressive or severe autoimmune disease (e.g., human immunodeficiency virus,&#xD;
             systemic lupus erythematosus, etc.). Note: corticosteroids are not included as&#xD;
             immunosuppressant therapy, diabetes mellitus is not regarded as autoimmune disease&#xD;
&#xD;
         15. Subject has previously received or is scheduled to receive radiotherapy to a coronary&#xD;
             artery (vascular brachytherapy), or the chest/mediastinum.&#xD;
&#xD;
         16. Subject has a platelet count &lt; 100,000 cells/mm^3 or &gt; 700,000 cells/mm^3.&#xD;
&#xD;
         17. Subject has renal insufficiency as defined as an estimated glomerular filtration rate&#xD;
             (GFR) &lt; 30 ml/min/1.73m^2 or dialysis at the time of consent.&#xD;
&#xD;
         18. Subject is high risk of bleeding for any reason; has a history of bleeding diathesis&#xD;
             or coagulopathy; has had a significant gastro-intestinal or significant urinary bleed&#xD;
             within the past six months.&#xD;
&#xD;
         19. Subject has had a cerebrovascular accident or transient ischemic neurological attack&#xD;
             (TIA) within the past 6 months, or any prior intracranial bleed, or any permanent&#xD;
             neurologic defect, or any known intracranial pathology (e.g. aneurysm, arteriovenous&#xD;
             malformation, etc.).&#xD;
&#xD;
         20. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath&#xD;
             insertion. Note: femoral arterial disease does not exclude the subject if radial&#xD;
             access may be used.&#xD;
&#xD;
         21. Subject has life expectancy &lt; 2 years.&#xD;
&#xD;
         22. Subject is, in the opinion of the Investigator or designee, unable to comply with the&#xD;
             requirements of the study protocol or is unsuitable for the study for any reason. This&#xD;
             includes completion of Subject Reported Outcome instruments.&#xD;
&#xD;
         23. Subject is currently participating in another clinical investigation (except for&#xD;
             non-invasive observational studies) that has not yet completed its primary endpoint.&#xD;
&#xD;
         24. Subject intends to participate in another investigational drug or device clinical&#xD;
             investigation (except for non-invasive observational studies) within 12 months after&#xD;
             the index procedure.&#xD;
&#xD;
         25. Subject has other medical illness (e.g., cancer or congestive heart failure) or known&#xD;
             history of substance abuse (alcohol, cocaine, heroin etc.) that may cause&#xD;
             non-compliance with the protocol, confound the data interpretation or is associated&#xD;
             with a limited life expectancy less than 2 years.&#xD;
&#xD;
         26. Presence of other anatomic or comorbid conditions, or other medical, social, or&#xD;
             psychological conditions that, in the investigator's opinion, could limit the&#xD;
             subject's ability to participate in the clinical investigation or to comply with&#xD;
             follow-up requirements, or impact the scientific soundness of the clinical&#xD;
             investigation results.&#xD;
&#xD;
         27. Subject has active symptoms and/or a positive test result of COVID-19 or other rapidly&#xD;
             spreading novel infectious agent within the prior 2 months.&#xD;
&#xD;
        Angiographic Exclusion Criteria:&#xD;
&#xD;
          1. Target lesion/vessel meets any of the following criteria:&#xD;
&#xD;
               -  Prevents complete angioplasty balloon (plain old balloon angioplasty [POBA],&#xD;
                  scoring balloon, or cutting balloon) inflation, such as:&#xD;
&#xD;
                    -  Heavy calcified lesion&#xD;
&#xD;
                    -  Requires additional device for lesion preparation (e.g. rotablator or&#xD;
                       laser).&#xD;
&#xD;
               -  Anatomy proximal to or within the lesion that prevents proper placement of&#xD;
                  delivery system:&#xD;
&#xD;
                    -  Extreme angulation (≥ 90°) proximal to or within the target lesion.&#xD;
&#xD;
                    -  Excessive tortuosity (≥ two 45° angles) proximal to or within the target&#xD;
                       lesion.&#xD;
&#xD;
               -  Involves a bifurcation of which the side branch will be jailed by the struts and&#xD;
                  requiring side branch pre-dilatation by Kissing Balloon Technique, and/or&#xD;
                  stenting&#xD;
&#xD;
               -  Is located:&#xD;
&#xD;
                    -  In left main or there is a ≥30% diameter stenosis in the left main (unless&#xD;
                       the left main lesion is a protected left main (i.e. a patent bypass graft to&#xD;
                       the left anterior descending coronary artery [LAD] and/or left circumflex&#xD;
                       coronary artery [LCX] arteries is present), and there is no intention to&#xD;
                       treat the protected left main lesion.&#xD;
&#xD;
                    -  Within 3 mm of the origin of the LAD or LCX.&#xD;
&#xD;
                    -  Within 3 mm of aorto-ostial right coronary artery (RCA).&#xD;
&#xD;
                    -  In a bypass graft or distal to anastomotic site of bypass graft.&#xD;
&#xD;
               -  With total occlusion (TIMI flow 0), prior to crossing with the wire.&#xD;
&#xD;
               -  Contains thrombus&#xD;
&#xD;
               -  The subject has been previously treated with a stent within 1-year prior to the&#xD;
                  index procedure such that the ABT NG DES 48 would need to cross the stent to&#xD;
                  reach the target lesion.&#xD;
&#xD;
          2. Unsuccessful target lesion pre-dilatation, defined as the presence of one or more of&#xD;
             the following:&#xD;
&#xD;
               -  Failed for a full inflation of the pre-dilatation balloon.&#xD;
&#xD;
               -  TIMI flow grade &lt;3 (per visual estimation).&#xD;
&#xD;
               -  Any angiographic complication (e.g. distal embolization, no-reflow)&#xD;
&#xD;
               -  Any dissection National Heart, Lung, and Blood Institute (NHLBI) grade D-F.&#xD;
&#xD;
               -  Any chest pain lasting &gt; 5 minutes.&#xD;
&#xD;
               -  Any ST-segment depression or elevation lasting &gt; 5 minutes.&#xD;
&#xD;
               -  Side branch requires additional dilatation/stenting caused by plaque shift,&#xD;
                  carina shift or may require additional dilatation/stenting after stent&#xD;
                  implantation, per the operator's assessment.&#xD;
&#xD;
          3. Non-target lesion meets any of the following criteria:&#xD;
&#xD;
               -  Is located in the target vessel&#xD;
&#xD;
               -  Is located in the left main location&#xD;
&#xD;
               -  Is restenotic from a previous stent implantation&#xD;
&#xD;
               -  Is located within a saphenous vein graft or an arterial graft&#xD;
&#xD;
               -  Is with a TIMI flow 0 (total occlusion) prior to guide wire crossing&#xD;
&#xD;
               -  Involves a complex bifurcation that needs two-stent strategy.&#xD;
&#xD;
          4. Treatment of non-target lesion is not deemed successful.&#xD;
&#xD;
        Note: A successful treatment is defined as a treatment resulted in a mean lesion diameter&#xD;
        stenosis &lt; 30% in 2 near-orthogonal projections with TIMI 3 flow, as visually assessed by&#xD;
        the physician, without the occurrence of prolonged chest pain or ECG changes consistent&#xD;
        with MI.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessie Coe</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ki E Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida/Malcom Randall VAMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chi-Jen Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steve Peck</last_name>
    <phone>9725269665</phone>
    <email>steven.peck@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lijuan Jenny Wang, PHD</last_name>
    <phone>4088453133</phone>
    <email>lijuan.wang1@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Toner</last_name>
      <phone>480-323-1046</phone>
      <email>btoner@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>David Rizik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bimal Padaliya, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scripps Memorial Hospital - La Jolla</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Weaver</last_name>
      <phone>858-824-8261</phone>
      <email>weaver.sharon@scrippshealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Cavendish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center Santa Monica</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ladda Douangvila</last_name>
      <phone>310-794-4797</phone>
      <email>ldouangvila@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Ravi Dave, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cardiac &amp; Vascular Institute Research Foundation, LLC</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Chavous</last_name>
      <phone>352-375-1212</phone>
      <email>KDChavous@tcavi.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Estel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shands at the University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Mohammed</last_name>
      <phone>352-273-8932</phone>
      <email>mohammed.mohammed@medicine.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Mohammad Massoomi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Redmond Regional Medical Center</name>
      <address>
        <city>Rome</city>
        <state>Georgia</state>
        <zip>30165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Jones</last_name>
      <phone>706-802-3139</phone>
      <email>kathy.jones6@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>George Myers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Via Christi Regional Medical Center - St. Francis Campus</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Korbe</last_name>
      <email>amber.korbe@cckheart.com</email>
    </contact>
    <investigator>
      <last_name>Bassem Chehab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Research Institute of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Korbe</last_name>
      <email>amber.korbe@cckheart.com</email>
    </contact>
    <investigator>
      <last_name>Aziz Maksoud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lina Fu</last_name>
      <phone>617-643-1371</phone>
      <email>lfu2@partners.org</email>
    </contact>
    <investigator>
      <last_name>Rahul Sakhuja, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>McMeans Amy</last_name>
      <phone>612-863-3895</phone>
      <email>amy.mcmeans@allina.com</email>
    </contact>
    <investigator>
      <last_name>Nicholas Burke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Jernigan</last_name>
      <phone>662-377-7572</phone>
      <email>anschmitz@nmhs.net</email>
    </contact>
    <investigator>
      <last_name>Barry Bertolet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Patrick Hospital</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelli Hoffman</last_name>
      <phone>406-327-1693</phone>
      <email>kelli.hoffman@providence.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Spoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Saint Vrestil</last_name>
      <phone>212-241-8228</phone>
      <email>nicole.saintvrestil@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Annapoorna Kini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NC Heart &amp; Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Pierre-Louis</last_name>
      <phone>919-784-7695</phone>
      <email>james.pierre-louis@unchealth.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Jobe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Medical Center Clinical Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelina Pack</last_name>
      <phone>336-713-2339</phone>
      <email>apack@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Applegate, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Lindner Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julianne O'Brien</last_name>
      <phone>513-585-0182</phone>
      <email>Julianne.Obrien@thechristhospital.com</email>
    </contact>
    <investigator>
      <last_name>Timothy Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Mercy Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Hickam</last_name>
      <phone>419-251-4919</phone>
      <email>michelle_hickam@mercy.com</email>
    </contact>
    <investigator>
      <last_name>Ameer Kabour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Heart &amp; Vascular Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Aiona</last_name>
      <phone>503-216-2099</phone>
      <email>heather.m.aiona@providence.org</email>
    </contact>
    <investigator>
      <last_name>Jason Wollmuth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health System</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gretchen Meise</last_name>
      <phone>717-920-4400</phone>
      <email>meisegc@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>William Bachinsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anmed Health</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonya Bair</last_name>
      <phone>864-512-8733</phone>
      <email>sonya.bair@anmedhealth.org</email>
    </contact>
    <investigator>
      <last_name>Brent McLaurin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Spears</last_name>
      <phone>865-455-7000</phone>
      <email>jill.spears@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Zachary George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Heart &amp; Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Roy</last_name>
      <phone>214-820-9903</phone>
      <email>angela.roy@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>James Choi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie McCracken</last_name>
      <phone>469-814-4717</phone>
      <email>julie.mccracken@baylorhealth.edu</email>
    </contact>
    <investigator>
      <last_name>Srinivasa Potluri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wheeling Hospital</name>
      <address>
        <city>Wheeling</city>
        <state>West Virginia</state>
        <zip>26003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Pietranton</last_name>
      <phone>304-243-8362</phone>
      <email>crystal.pietranton@wvumedicine.org</email>
    </contact>
    <investigator>
      <last_name>Deepak Hooda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>natalia Inness</last_name>
      <phone>+61 2 8738 3811</phone>
      <email>natalia.inness@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Sidney Lo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Mearns</last_name>
      <phone>(073) 139-4711</phone>
      <email>megan.mearns@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Estelle Beevors</last_name>
      <email>estelle.beevors@health.qld.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher Raffel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Dent</last_name>
      <phone>61294632425</phone>
      <email>jill.dent@health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Emma Reid</last_name>
      <phone>61294632519</phone>
      <email>emma.reid@health.nsw.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Ravinay Bhindi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Linkou</city>
        <state>North Taiwan</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pin-Chen Chen</last_name>
      <phone>886939386800</phone>
      <email>pcc1801@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chi-Jen Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <state>North Taiwan</state>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hsin-Yu Tang</last_name>
      <email>s309272001@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yi-Chih Wang, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cheng Hsin General Hospital</name>
      <address>
        <city>Taipei</city>
        <state>North Taiwan</state>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling-Zhi Chang</last_name>
      <email>apap03311@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tien-Ping Tsao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <state>South Taiwan</state>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miao-Huan Chen</last_name>
      <phone>092-962-0978</phone>
      <email>afen101@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Chiung-Jen Wu, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>De novo native coronary artery long lesions</keyword>
  <keyword>ABT NG DES 48 EECSS</keyword>
  <keyword>ABT-CIP-10321</keyword>
  <keyword>Coronary artery luminal diameter</keyword>
  <keyword>SPIRIT 48</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

